A Phase 4 interventional study of letrozole in Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 48 sites in United States. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.
Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 39th largest by enrollment of the 159 interventional ones that give a count, is one of 10 that started in 2008, is one of 17 in phase 4, and was the 58th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fujian Cancer Hospital · Sites in China
Ages 18+ · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75 · Women only
Celcuity Inc · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 50 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 83 · Phase 3 45 · Phase 4 17
First in 1998; this study’s year is marked. 10 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 95 across the 159 interventional studies. Of the 109 that completed or were terminated, 44 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 162 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 47th largest by enrollment of the 155 interventional ones that give a count, is one of 8 that started in 2008, is one of 17 in phase 4, and was the 56th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
8 of the studies testing letrozole in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04486911Shengjing HospitalPyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | 2026-12-01 |
| NCT05286437National Cancer Centre, SingaporePhase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
| NCT02562118National University Hospital, SingaporeNeoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 162 studies testing letrozole in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole
This is a multi-center prospective non-randomized single arm, open label trial in postmenopausal HR positive early breast cancer patients who experience grade 2-3 arthralgia-myalgia while on anastrozole, resulting in the discontinuation of anastrozole. After a 2-3 week period without any aromatase inhibitor treatment, eligible patients will initiate letrozole treatment at a dose of 2.5mg per day for a duration of 24 weeks. If a patient has breast cancer recurrence or is intolerant to letrozole during the 24 week period, the drug will be discontinued.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
women with HR+ early stage breast cancer at the time of initial diagnosis. For study purposes, postmenopausal is defined as:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.
Drug: letrozole
2.5 mg daily by mouth for 6 months
Also known as: Femara
Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia.
The arthralgia status and the myalgia status were separately graded at Baseline (V1), Week 12 (V3) , and Week 24/EOS (V4). The grades of 0 for no pain, 1 for mild pain, 2 for moderate pain, 3 for severe pain, and 4 for disabling pain were used.
Time frame: End of Study (24 weeks)
Time to Discontinuation Due to Grade 2 or Higher Arthralgia- Myalgia.
For patients who discontinued from the study due to either grade 2 or higher arthralgia-myalgia, the time to discontinuation was calculated as the duration between the Visit 1 date and the last dose date. If the last dose date was missing, the EOS date was used.
Time frame: End of Study (24 weeks)
Percentage of Participants Discontinuing, Irrespective of Cause
The percentage of patients who discontinued from the study irrespective of the reasons.
Time frame: End of Study (24 weeks)
Change in Brief Pain Inventory (BPI) Composite Score
The BPI is a pain assessment tool for use with cancer patients. The BPI measures both the intensity of pain (sensory dimension) and interference of pain in the patient's life (reactive dimension). It also queries the patient about pain relief, pain quality, and patient perception of the cause of pain. The BPI composite score was calculated based on questions 3 to 6 of the BPI Questionnaire (short form). First each question was scored from 0 (no pain) to 10 (pain as bad as you can imagine) and circled on the CRF. Then a composite score was calculated as the mean of the scores. If any answer was missing, the composite score was set to missing. Change in BPI composite score indicates the change from baseline at week 24.
Time frame: Baseline, 24 weeks (End of Study)
Change in Disability Index as Assessed by Health Assessment Questionnaire (HAQ)
The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The Stanford HAQ 20-item disability scale was utilized for scoring of the Disability Index. The items were first scored within each category with values 0 to 3 (0 = Without any difficulty, 1 = With some difficulty, 2 = With much difficulty, 3 = Unable to do). The score for the disability index was the mean of the eight category scores. If more than 2 of the 8 categories, or \>25%, were missing, the scale was not scored. If ≤2 of the categories were missing, the sum of the categories was divided by the number of answered categories. Change in Disability Index indicates the change from baseline at week 24.
Time frame: Baseline, Visit 1(24 weeks = End of Study)
Change in Pain as Assessed by Visual Analog Scale (VAS) Scale of the Health Assessment Questionnaire (HAQ)
The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The VAS is a tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 \[100-mm scale\]). A higher score indicates greater pain intensity. Change in pain as assessed by VAS indicates the change from baseline at week 24.
Time frame: Baseline, Visit 1 (24 weeks = End of Study)
The study enrolled 261 participants at 45 centers in United States.
| Milestone | Letrozole |
|---|---|
| Started | 261 |
| Completed | 228 |
| Not completed | 33 |
| Withdrew: Adverse event | 28 |
| Withdrew: Patient withdrew consent | 2 |
| Withdrew: Administrative problems | 1 |
| Withdrew: Protocol violation | 2 |
The arthralgia status and the myalgia status were separately graded at Baseline (V1), Week 12 (V3) , and Week 24/EOS (V4). The grades of 0 for no pain, 1 for mild pain, 2 for moderate pain, 3 for severe pain, and 4 for disabling pain were used.
| Participants | Letrozole |
|---|---|
| Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia. | 25 |
For patients who discontinued from the study due to either grade 2 or higher arthralgia-myalgia, the time to discontinuation was calculated as the duration between the Visit 1 date and the last dose date. If the last dose date was missing, the EOS date was used.
| days | Letrozole |
|---|---|
| Time to Discontinuation Due to Grade 2 or Higher Arthralgia- Myalgia. | 156.98 ± 1.94 |
The percentage of patients who discontinued from the study irrespective of the reasons.
| Participants | Letrozole |
|---|---|
| Percentage of Participants Discontinuing, Irrespective of Cause | 33 |
The BPI is a pain assessment tool for use with cancer patients. The BPI measures both the intensity of pain (sensory dimension) and interference of pain in the patient's life (reactive dimension). It also queries the patient about pain relief, pain quality, and patient perception of the cause of pain. The BPI composite score was calculated based on questions 3 to 6 of the BPI Questionnaire (short form). First each question was scored from 0 (no pain) to 10 (pain as bad as you can imagine) and circled on the CRF. Then a composite score was calculated as the mean of the scores. If any answer was missing, the composite score was set to missing. Change in BPI composite score indicates the change from baseline at week 24.
| score on a scale | Letrozole |
|---|---|
| Baseline visit | 2.78 ± 2.00 |
| Week 24 | -0.46 ± 2.09 |
The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The Stanford HAQ 20-item disability scale was utilized for scoring of the Disability Index. The items were first scored within each category with values 0 to 3 (0 = Without any difficulty, 1 = With some difficulty, 2 = With much difficulty, 3 = Unable to do). The score for the disability index was the mean of the eight category scores. If more than 2 of the 8 categories, or \>25%, were missing, the scale was not scored. If ≤2 of the categories were missing, the sum of the categories was divided by the number of answered categories. Change in Disability Index indicates the change from baseline at week 24.
| score on a scale | Letrozole |
|---|---|
| Visit 1 (Baseline visit) | 0.54 ± 0.55 |
| Visit 4 (Week 24) | -0.07 ± 0.47 |
The HAQ is a validated, patient-oriented outcome assessment instrument. The short version '2 page HAQ' was used. It contains the HAQ Disability Index (HAQ-DI), the HAQ visual analog scale (VAS) for pain and the VAS patient global health scale. The VAS is a tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 \[100-mm scale\]). A higher score indicates greater pain intensity. Change in pain as assessed by VAS indicates the change from baseline at week 24.
| score on a scale | Letrozole |
|---|---|
| Visit 1 (Baseline visit) | 28.9 ± 24.22 |
| Visit 4 (Week 24) | -6.4 ± 29.30 |
Collected over Adverse events were collected From Start of the Study up to EOS (Week 24). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Letrozole 2.5 mg | 0/261 (0%) | 5/261 (1.9%) | 163/261 (62.5%) |
| Event | Letrozole 2.5 mg |
|---|---|
| Cholecystitis chronicHepatobiliary disorders | 1/261 |
| Post procedural bile leakInjury, poisoning and procedural complications | 1/261 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 1/261 |
| DepressionPsychiatric disorders | 1/261 |
| ManiaPsychiatric disorders | 1/261 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/261 |
| Event | Letrozole 2.5 mg |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 88/261 |
| MyalgiaMusculoskeletal and connective tissue disorders | 78/261 |
| Hot flushVascular disorders | 37/261 |
| FatigueGeneral disorders | 32/261 |
| NauseaGastrointestinal disorders | 13/261 |
| DepressionPsychiatric disorders | 13/261 |
| Oedema peripheralGeneral disorders | 10/261 |
| ConstipationGastrointestinal disorders | 8/261 |
| DiarrhoeaGastrointestinal disorders | 8/261 |
| HeadacheNervous system disorders | 8/261 |
| Age, Continuous(years) | Letrozole |
|---|---|
| Mean | 61.6 ± 10.2 |
| Sex/Gender, Customized(Participants) | Letrozole |
|---|---|
| Female | 261 |
| Race/Ethnicity, Customized(Participants) | Letrozole |
|---|---|
| Caucasian | 235 |
| Black | 14 |
| Asian | 3 |
| Other | 9 |
| Relevant Medical and Surgical History(Participants) | Letrozole |
|---|---|
| Yes | 261 |
| No | 0 |
| Rheumatology History(Participants) | Letrozole |
|---|---|
| Yes | 261 |
| No | 0 |
The record gives a start of Mar 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 11 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole